KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Thermo Fisher Scientific (TMO) Non-Current Assets (2016 - 2025)

Thermo Fisher Scientific's Non-Current Assets history spans 17 years, with the latest figure at $81.6 billion for Q4 2025.

  • For the quarter ending Q4 2025, Non-Current Assets rose 8.58% year-over-year to $81.6 billion, compared with a TTM value of $314.7 billion through Dec 2025, up 5.51%, and an annual FY2025 reading of $81.6 billion, up 8.58% over the prior year.
  • Non-Current Assets for Q4 2025 was $81.6 billion at Thermo Fisher Scientific, up from $80.7 billion in the prior quarter.
  • The five-year high for Non-Current Assets was $81.6 billion in Q4 2025, with the low at $48.2 billion in Q2 2021.
  • Average Non-Current Assets over 5 years is $71.0 billion, with a median of $74.0 billion recorded in 2022.
  • Year-over-year, Non-Current Assets surged 59.27% in 2021 and then dropped 4.11% in 2022.
  • Tracing TMO's Non-Current Assets over 5 years: stood at $75.0 billion in 2021, then fell by 4.11% to $71.9 billion in 2022, then rose by 3.08% to $74.1 billion in 2023, then increased by 1.41% to $75.2 billion in 2024, then increased by 8.58% to $81.6 billion in 2025.
  • Per Business Quant, the three most recent readings for TMO's Non-Current Assets are $81.6 billion (Q4 2025), $80.7 billion (Q3 2025), and $76.6 billion (Q2 2025).